ImmuCell Announces Product Sales Growth and Other Financial Results for Second Quarter of 2011
(firmenpresse) - PORTLAND, ME -- (Marketwire) -- 08/15/11 -- (NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2011.
During the three-month period ended June 30, 2011, product sales increased by 16%, or $170,000, to $1,247,000 in comparison to the same period in 2010. During this current period, animal health sales increased by 32%. During the six-month period ended June 30, 2011, product sales increased by 17%, or $414,000, to $2,803,000 in comparison to the same period in 2010. During this current period, animal health sales increased by 24%. During the twelve-month period ended June 30, 2011, product sales increased by 8%, or $363,000, to $4,800,000 in comparison to the same period in 2010. During this current period, animal health sales increased by 12%.
"A 28% increase in sales of our lead product, ®, during the first six months of 2011 over the same period in 2010 demonstrates a solid return on our increased investment in sales and marketing," commented Michael F. Brigham, President and CEO. "This growth in our commercial business is important to us while we seek a partner to work with to complete the development of ®."
Mr. Brigham further commented, "Our strategic decision to internally fund the development of ® to the point where we anticipate engaging a partner has resulted in net operating losses from 2008 through the second quarter of 2011. As we advance ® to the final stages of the product approval process and anticipate reducing our internal funding of this program, we expect to return to net operating income."
Due principally to ® product development expenses, the loss before income taxes was $457,000 during the three-month period ended June 30, 2011, in comparison to a loss before income taxes of $37,000 during the same period in 2010. The net loss was $258,000, or $0.09 per share, during the three-month period ended June 30, 2011, in comparison to a net loss of $6,000, or less than $0.01 per share, during the same period in 2010.
Due principally to ® product development expenses, the loss before income taxes was $488,000 during the six-month period ended June 30, 2011, in comparison to a loss before income taxes of $102,000 during the same period in 2010. The net loss was $281,000, or $0.09 per share, during the six-month period ended June 30, 2011, in comparison to a net loss of $60,000, or $0.02 per share, during the same period in 2010.
Cash, cash equivalents and short-term investments increased by 10%, or $449,000, to $5,075,000 at June 30, 2011 as compared to $4,626,000 at December 31, 2010. Stockholders' equity decreased by 3%, or $238,000, to $9,045,000 at June 30, 2011 as compared to $9,282,000 at December 31, 2010. The Company had 2,981,000 shares of common stock outstanding as of June 30, 2011.
The foregoing press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 concerning ImmuCell's partnering strategy and return to profitability. Factors that could cause the Company's future results to differ materially from those described in the forward-looking statements, together with other risk factors, are detailed from time to time in filings we make with the Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Forward-looking statements in this press release are based on our current information and expectations. Actual results may differ materially due to various factors, including those risks.
About ImmuCell:
ImmuCell Corporation's (NASDAQ: ICCC) purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site, ().
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.08.2011 - 06:00 Uhr
Sprache: Deutsch
News-ID 1030419
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
PORTLAND, ME
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ImmuCell Announces Product Sales Growth and Other Financial Results for Second Quarter of 2011
"
steht unter der journalistisch-redaktionellen Verantwortung von
ImmuCell Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
